RE: Hypothetical question1 Nov 2024 07:48
Any offer that comes in instantly validates the tech so if it's worth £2 a share then it's worth £10 a share if that makes sense.
I'm sure if Novartis stuck in a £10 per share offer the likes of Pfizer, Lily, Roche etc.. would just sit back and be like "oh hey, look at them go, buying the keys to revolutionise the treatment of cancer" then watch their own drugs become obsolete over the proceeding years lol
The technology is worth what it's worth and one way or another it will find the correct valuation.